See the DrugPatentWatch profile for Ingrezza
Ingrezza Market Share in 2023 and 2024
Estimates for Ingrezza's market share in 2023 and 2024 are not publicly available in precise figures. However, its sales performance indicates significant growth within its therapeutic areas. In the first quarter of 2024, Ingrezza achieved $552.8 million in sales [1]. This represents a 32% increase compared to the same period in 2023, when sales were $418.8 million [1]. This consistent upward trend suggests an expanding market presence for the drug.
What is driving Ingrezza's sales growth?
Ingrezza's sales growth is primarily attributed to its efficacy in treating tardive dyskinesia (TD) and chorea associated with Huntington's disease (HD) [1]. The drug's performance in the first quarter of 2024 was particularly strong, exceeding analyst expectations [1]. This suggests increasing physician adoption and patient utilization.
When does Ingrezza's patent expire?
The patent landscape for Ingrezza is complex, with multiple patents covering the drug and its uses. According to DrugPatentWatch.com, several key patents related to Ingrezza are set to expire in the coming years [2]. For instance, patents covering the composition of matter and methods of treatment are listed with various expiry dates, some extending into the late 2030s [2]. The specific expiry dates and their implications for market exclusivity are subject to ongoing legal and regulatory factors.
What is the therapeutic area for Ingrezza?
Ingrezza (valbenazine) is a selective VMAT2 inhibitor approved for the treatment of tardive dyskinesia [1]. It is also indicated for chorea associated with Huntington's disease [1]. Tardive dyskinesia is a movement disorder characterized by involuntary, repetitive movements, often a side effect of long-term use of antipsychotic medications [3]. Chorea associated with Huntington's disease is also a type of involuntary hyperkinetic movement [4].
How does Ingrezza compare to other treatments for tardive dyskinesia?
While precise head-to-head market share comparisons are not readily available, Ingrezza is a leading treatment option for tardive dyskinesia. Other treatments for TD may include dose reduction or discontinuation of the offending antipsychotic medication, or the use of other medications that can help manage involuntary movements. Ingrezza's mechanism of action, targeting the VMAT2 transporter, offers a specific approach to managing TD symptoms.
What are the potential risks and side effects of Ingrezza?
Common side effects of Ingrezza include somnolence and somnolence-related events [3]. Other reported side effects can include dry mouth, constipation, headache, and urinary tract infection [3]. Patients should discuss any potential risks and side effects with their healthcare provider.
Who manufactures Ingrezza?
Ingrezza is manufactured by Neurocrine Biosciences [1].
Sources
1. Neurocrine Biosciences. (2024, April 29). Neurocrine Biosciences Reports First Quarter 2024 Financial Results. https://ir.neurocrine.com/news-releases/news-release-details/neurocrine-biosciences-reports-first-quarter-2024-financial-results
2. DrugPatentWatch.com. (n.d.). Ingrezza Patent Expirations. https://drugpatentwatch.com/ingrezza-patent-expirations
3. U.S. Food and Drug Administration. (n.d.). Ingrezza (valbenazine) Prescribing Information.
4. National Institute of Neurological Disorders and Stroke. (n.d.). Huntington's Disease Fact Sheet.